Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova's lead compound, rigosertib, are aimed at unmet medical needs of patients with myelodysplastic syndromes (MDS).
Pivotal Phase lll trial INSPIRE on four continents for small molecule lead drug candidate rigosertib.
Unique mechanism targets Ras pathways, the most sought after targets in oncology.
Despite incidence of over 18,000 patients, no advancements in MDS in more than a decade.
Current therapeutic options are not curative and carry many side effects.
INSPIRE trial is focused on identified sub-population of patients where the drug was highly effective.
Rigosertib is protected by issued patents and has been awarded Orphan Designation for MDS in the United States, Europe and Japan.
Oral rigosertib, in combination with azacitidine, is being developed for a much larger patient population.
Phase lll combination trial expected to launch in the second half of 2017, following a successful advisory meeting with the FDA.
Broad pipeline with clinical and several pre-clinical stage drug candidates.